Barclays Issues Pessimistic Forecast for Humacyte (NASDAQ:HUMA) Stock Price

Humacyte (NASDAQ:HUMA) had its price objective dropped by equities researchers at Barclays from $3.50 to $1.50 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 131.84% from the company’s current price.

Several other brokerages also recently commented on HUMA. BTIG Research lowered their target price on shares of Humacyte from $6.00 to $3.00 and set a “buy” rating for the company in a report on Friday, March 27th. Benchmark lowered their target price on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Humacyte in a report on Monday, December 29th. Wall Street Zen downgraded shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $7.43.

Humacyte Stock Up 6.6%

Shares of Humacyte stock traded up $0.04 on Wednesday, hitting $0.65. The company had a trading volume of 1,872,878 shares, compared to its average volume of 6,761,642. The stock has a market capitalization of $143.65 million, a price-to-earnings ratio of -3.24 and a beta of 2.11. Humacyte has a 1 year low of $0.55 and a 1 year high of $2.93. The stock has a 50 day moving average of $0.98 and a 200-day moving average of $1.23. The company has a debt-to-equity ratio of 20.08, a quick ratio of 0.90 and a current ratio of 3.69.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.35 million. Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%. As a group, sell-side analysts forecast that Humacyte will post -1.27 earnings per share for the current year.

Institutional Trading of Humacyte

A number of large investors have recently bought and sold shares of the company. Beacon Pointe Advisors LLC increased its position in Humacyte by 28.6% in the second quarter. Beacon Pointe Advisors LLC now owns 36,000 shares of the company’s stock worth $75,000 after buying an additional 8,000 shares during the last quarter. Concurrent Investment Advisors LLC increased its position in Humacyte by 16.6% in the third quarter. Concurrent Investment Advisors LLC now owns 59,615 shares of the company’s stock worth $104,000 after buying an additional 8,500 shares during the last quarter. SG Americas Securities LLC increased its position in Humacyte by 50.3% in the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock worth $33,000 after buying an additional 11,411 shares during the last quarter. Independent Advisor Alliance increased its position in Humacyte by 49.4% in the third quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after buying an additional 11,991 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new stake in Humacyte in the second quarter worth $28,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.